Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ: JAZZ) insider transactions

In the twelve months to 10 November 2026, executives and directors of Jazz Pharmaceuticals reported 67 open-market sales of 414,345 shares ($87.9m) and 0 open-market purchases, by 11 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Jazz Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 November 2026Cozadd Bruce CDirectorOption exercise+734$136.18340,609Form 4
6 November 2026Cozadd Bruce CDirectorOption exercise+85,766$136.18426,375Form 4
6 November 2026Cozadd Bruce CDirectorOpen-market sale−27,714$234.91398,661Form 4
6 November 2026Cozadd Bruce CDirectorOpen-market sale−10,688$235.82387,973Form 4
6 November 2026Cozadd Bruce CDirectorOpen-market sale−24,483$236.84363,490Form 4
6 November 2026Cozadd Bruce CDirectorOpen-market sale−5,923$237.39357,567Form 4
4 November 2026Carr PatriciaSVP, Chief Accounting OfficerOption exercise+1,250$140.037,925Form 4
4 November 2026Carr PatriciaSVP, Chief Accounting OfficerOpen-market sale−1,250$231.376,675Form 4
4 November 2026Carr PatriciaSVP, Chief Accounting OfficerOpen-market sale−163$231.276,512Form 4
3 November 2026Gala Renee DPresident & CEOOpen-market sale, 10b5-1 plan−1,000$225.37140,394Form 4
2 November 2026Cozadd Bruce CDirectorOpen-market sale, 10b5-1 plan−6,000$215.84339,875Form 4
6 October 2026Gala Renee DPresident & CEOOpen-market sale, 10b5-1 plan−2,000$236.40141,394Form 4
1 October 2026Cozadd Bruce CDirectorOpen-market sale, 10b5-1 plan−6,000$230.33345,875Form 4
10 September 2026Patil Neena MEVP & Chief Legal OfficerOpen-market sale, 10b5-1 plan−1,200$240.9447,671Form 4
8 September 2026Gala Renee DPresident & CEOShares withheld for tax, 10b5-1 plan−1,967$246.81145,394Form 4
8 September 2026Gala Renee DPresident & CEOOpen-market sale, 10b5-1 plan−2,000$243.03143,394Form 4
8 September 2026Henderson Mary ElizabethSVP, Technical OperationsShares withheld for tax−1,412$243.0323,830Form 4
8 September 2026Henderson Mary ElizabethSVP, Technical OperationsShares withheld for tax−15$241.2023,815Form 4
1 September 2026Cozadd Bruce CDirectorOpen-market sale, 10b5-1 plan−6,000$250.13351,875Form 4
31 August 2026Riedel Norbert GDirectorShares withheld for tax−14$244.648,615Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Jazz Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.